According to Spain’s avant garde on September 1, research shows that after decades of efforts, the effectiveness of influenza vaccine has not exceeded 50%. < / P > < p > two years ago, before the new coronavirus became the focus of the world’s attention, in Spain alone, the influenza virus caused about 15000 deaths and led to 52000 patients having to be hospitalized. In order to achieve the goal of effective prevention of new coronavirus, improving the effectiveness of influenza vaccine is still a problem. In the better years, the effective rate of influenza vaccine in vaccinators can reach 50% to 60%. However, in 2018, its efficiency is only 25%. < / P > < p > influenza virus is an elusive, very diverse and rapidly mutating virus, so it can keep the same pace and pace with the new vaccines developed every year in the competition with the human immune system. One of the main goals of vaccines is to inhibit the hemagglutinin protein that helps influenza virus adhere to human cells. Unfortunately, however, this protein has a strong ability to mutate and evade vaccine attack. On August 31, a group of researchers led by Ali elbedi of Washington University in St. Louis published a research report in the journal Nature, focusing on why most people are not immunized and how to improve strategies. One reason why most people are not immune may be that people have been infected with these common influenza viruses. Since the vaccines developed each year tend to target the most common influenza at that time, they can only stimulate the immune system to respond to the virus strains that the vaccinators have been infected with in the past, rather than to the new virus strains. < / P > < p > in order to find a more effective vaccine, researchers have carried out research on lymph nodes, which are similar to the “training center” of B lymphocytes. When the virus invades the lymph nodes, these lymphocytes produce antibodies to fight the virus. Once our bodies come into contact with the pathogen, they store memories of the virus so that they can react more quickly when they come into contact later. This usually works for less severe infections, but may also lead to reduced vaccine effectiveness. “These memory cells can respond to the part of the virus that has not changed compared to the previous strain, and our goal now is to focus the immune response on the part of the virus that changes every year,” erebedi said < / P > < p > the researchers invited eight volunteers who had been vaccinated against influenza between 2018 and 2019 to test a new vaccine. In most cases, the vaccine stimulated B lymphocytes that had been “trained” by the previous vaccine to react, but only three volunteers produced new B lymphocytes, which in turn had a specific response to the new virus strain. “Our research shows that the flu vaccine can stimulate two types of B lymphocytes to respond, but we don’t know what the probability of this happening is,” erebedi said He pointed out that these lymph nodes are the key to increasing the proportion of patients ultimately protected by the flu vaccine.